Trial Profile
An Open Label, Multicenter, Randomized, Phase III Comparator Study of Oral Topotecan Versus Intravenous Topotecan for Second Line Therapy in Patients With Small Cell Lung Cancer Who Have Relapsed Greater Than or Equal to 90 Days After Completion of First Line Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Topotecan (Primary) ; Topotecan (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 20 May 2007 Status changed from in progress to completed
- 15 Sep 2005 New trial record.